search query: @author Schonfeld, E. / total: 5
reference: 5 / 5
« previous | next »
| Author: | Schonfeld, E. |
| Title: | The new biotech boom: A star is born |
| Journal: | Fortune
1997 : JAN, VOL. 135:1, p. 52-57 |
| Index terms: | BIO-TECHNOLOGY INDUSTRY BIO-TECHNOLOGY STOCK MARKETS |
| Language: | eng |
| Abstract: | EntreMed's stock is valued more on news flow than cash, like most biotech companies, but after signing a $ 76 million partnership agreement with Bristol-Meyers Squibb they had credibility enough to go public. The scientist-entrepreneurs have learned establish credibility: cutting deals with pharmaceuticals companies, establish links with brand-name scientists. EntreMed's concept was to be a clearinghouse for other people's science and after a while they got rights to commercialize some of the most promising research being done by one of the world's best-known scientists. There is a natural marriage between biotech and major drug companies. Pharmaceuticals companies are cash-generating manufacturers and marketers searching for innovative products to push through their factories and distribution channels. The deal with EntreMed may not be a surprise. |
« previous | next »
SCIMA